Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-03-11

Clinical Trial Update: Apixaban in Patients With Sickle Cell Disease [Phase 3]

View source ↗

Summary

Phase 3 trial update for apixaban in sickle cell disease was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Apixaban (apixaban)

Snippet

Sponsor: Nirmish Shah | Conditions: Vaso-occlusive Crisis, Reduction in Hospitalizations | Phase 3 | Status: TERMINATED | Results posted: 2020-03-11